DUBLIN, March 26, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/bn9wlv/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019" report to their offering.
An antibacterial drug is referred to as an agent that interferes with the growth and reproduction of bacteria that cause numerous mild to severe infections in humans. These agents possess bactericidal activity which target various parts of bacterial physiology such as protein synthesis, cell wall synthesis, nucleic acid synthesis and permeability of cell membrane, and therefore help in treating infections. Antibacterial drugs have been utilized by humans since the discovery of first antibacterial in the form of penicillin in 1928 and presently there are a lot of antibacterial drugs available for the treatment of various indications like pneumonia, tuberculosis, tetanus, diphtheria, diarrhea, legionellosis and other diseases.
The global antibacterial drugs market has been categorized into seven segments based on their class, namely, aminoglycosides, ß-lactams, tetracyclines, sulfonamides, quinolones/ fluoroquinolones, macrolides and phenicols. In 2012, ß-lactams class occupied the leading position with a share of 57.1% of the global antibacterial drugs market followed by the quinolones. However, these drug classes are expected to witness decline in their market share during the forecast period due to patent expiry of key branded formulations and growing number of drug resistant bacterial strains.
Hence, on account of the above mentioned factors, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2013 to 2019. However, growing demand for therapies against bacterial infections and rising elderly populations are some of the factors that are anticipated to maintain steady growth of the antibacterial drugs market. Additionally, expected launch of various antibacterial agents that are currently in developmental stages, such as tedizolid (Cubist Pharmaceuticals), Dalvance (Durata Therapeutics), surotomycin (Cubist Pharmaceuticals), MK-3415A (Merck) during the forecast period is also expected to restore growth of this market.
Asia-Pacific held the largest share of the revenue generated by the global antibacterial drugs market in 2012. This region is also expected to experience the highest growth rate during the forecast period 2013 to 2019. The major factors responsible for this region to hold leadership position in this market in 2012 include presence of large number of generic manufacturers in Asian countries, growing incidences of bacterial infections such as MRSA (methicillin resistant Staphylococcus aureus) and C. difficile and increasing purchasing power of the people of this region.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million)
Chapter 5 Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million)
Chapter 6 Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million)
Chapter 7 Competitive Landscape
Chapter 8 Recommendations
Chapter 9 Company Profiles
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Forest Laboratories, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
For more information visit http://www.researchandmarkets.com/research/bn9wlv/antibacterial
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets